Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin effects on cholesterol and glucose fluxes in type 2 diabetes
NL-OMON43515Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dapagliflozin and rosuvastatin in type 2 diabetes mellitus (T2DM) and dyslipidemia, sponsored by Amsterdam University Medical Center. Primary endpoint: Effect on LDL de novo lipogenesis. Started Sep 2016; status: active, not recruiting.
02
Drugs
dapagliflozinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NL-OMON43515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43515.